Related Experiment Video
Updated: May 20, 2026
08:27
Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
Unlabeled multi tumor marker detection system based on bioinitiated light addressable potentiometric sensor
Yun-Fang Jia1, Chun-Ying Gao, Jia He
1College of Information Science Technology, Nankai University, 300071, China. jiayunfang@yahoo.com.cn
The Analyst
|July 7, 2012
Summary
This study introduces a novel label-free biosensor for simultaneously detecting multiple tumor markers. The light addressable potentiometric sensor (LAPS) system offers a promising new method for clinical cancer diagnosis.
Area of Science:
- Biomedical Engineering
- Biosensor Technology
- Clinical Diagnostics
Background:
- Multiplex biomarker assays are crucial for accurate clinical diagnosis.
- Existing methods often require labels, increasing complexity and cost.
- Need for sensitive, label-free detection systems for multiple tumor markers.
Purpose of the Study:
- To develop and validate a label-free, multi-tumor marker parallel detection system.
- To utilize a light addressable potentiometric sensor (LAPS) platform for enhanced sensitivity.
- To assess the system's potential for clinical application in cancer diagnostics.
Main Methods:
- Fabrication of arrayed LAPS chips on silicon wafers.
- Surface initiation using L-Dopa and biofunctionalization with tumor marker antigens/antibodies (AFP, CEA, CA19-9, Ferritin).
- Label-free detection of unlabeled antigens and antibodies using the developed system.
Main Results:
- Successful development of a user-friendly, label-free parallel detection system.
- Demonstrated detection of four key tumor markers (AFP, CEA, CA19-9, Ferritin) without labels.
- Comparison of measured response ranges with clinical cutoff values, showing potential sensitivity.
Conclusions:
- The bioinitiated LAPS-based system enables label-free, multiplexed detection of tumor markers.
- This technology presents a viable alternative for clinical assays of multiple cancer biomarkers.
- Potential for improved efficiency and reduced cost in cancer diagnostics.
